Recent Press Releases

Depomed Comments on Horizon Withdrawal of Offer to Acquire Company

NEWARK, Calif., Nov. 19, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today issued the following statement regarding Horizon Pharma plc's...

Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP

ZUG, Switzerland--(BUSINESS WIRE)-- Biogen (BIIB) today announced further progress as part of its commitment to biosimilars. Samsung Bioepis, the joint venture between Samsung Biologics and Biogen,...

Narcan (Naloxone Hydrochloride) Nasal Spray Approved By U.S. Food and Drug Administration

Narcan (Naloxone Hydrochloride) Nasal Spray Approved By U.S. Food and Drug Administration First Ready-to-Use Needle-Free Nasal Spray Treats Opioid Overdose Emgergency Dublin, Ireland -- November 19,...

Mallinckrodt plc Board Adds $500 Million To Company's Existing Share Repurchase Program

-- Supplements approximately $200 million remaining under current share repurchase plan -- -- Board also authorizes management to reduce debt at its discretion -- -- Leverages Mallinckrodt's...

Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition

· $ 17 billion acquisition establishes leading player in life science industry · New entity to enhance product range, capabilities and geographic reach ·...

FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose

Naloxone in nasal spray form provides important new alternative for family members, first responders Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved...

NICE issues draft guidance on evolocumab for lipid disorder

NICE issues draft guidance on evolocumab for lipid disorder 18 November 2015 NICE has published draft guidance not recommending evolocumab (Repatha, Amgen) as an option for people with high...

U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma

Submission based on overall survival data from CheckMate -025, a Phase 3 study comparing Opdivo versus everolimus in this patient population Agency previously granted Opdivo Breakthrough Therapy...

NICE: Kadcyla price still too high

NICE: Kadcyla price still too high 17 November 2015 Although retained for use through the Cancer Drugs Fund, Roche's breast cancer combination treatment, Kadcyla (trastuzumab emtansine), will not be...

Allergan Partners with CDC to Spread the Word about Antibiotic Stewardship During "Get Smart About Antibiotics Week"

- Eighth-annual global observance will raise awareness of the threat of antibiotic resistance and the importance of appropriate antibiotic use across all healthcare settings - DUBLIN, Nov. 17, 2015...

DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma

First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who...

Statement of Matthew Cantor, Attorney for Irmat Pharmacy

On November 12, 2015, Irmat Pharmacy, located in New York City, asked a New York court to halt what it views as an illegal and anticompetitive termination of its enrollment as a participating...

Mylan Authorizes $1 Billion Share Repurchase Plan

HERTFORDSHIRE, England and PITTSBURGH, Nov. 16, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE; MYL) today announced that the Board of Directors of Mylan N.V. (the "Company") has authorized...

Perrigo Shareholders Convincingly Reject Mylan's Tender Offer, Expressing Confidence in Perrigo's Long-Term Strategy

DUBLIN, Nov. 13, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to the news that holders of a majority of its shares...

Mylan Announces Results of Offer to Acquire Perrigo and Lapse of Offer

HERTFORDSHIRE, England and PITTSBURGH, Nov. 13, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL; TASE) today announced that its offer to acquire all of the issued and to be issued share capital of...

Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation

Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation KENILWORTH, N.J.--(BUSINESS WIRE)--Nov. 12, 2015 - Merck (NYSE:MRK), known as MSD outside the United States and...

U.S. FDA Approves New Indications for Harvoni, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C

U.S. FDA Approves New Indications for Harvoni, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C – Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients...

Horizon Pharma plc Provides Comment on Express Scripts' Business Practices

DUBLIN, IRELAND -- (Marketwired) -- 11/11/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...

Express Scripts statement on Linden Care

We have removed the Linden Care pharmacy from our network. In our research, we found that it predominantly dispensed Horizon prescription drugs and did not fulfill key components of our pharmacy...

Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

THOUSAND OAKS, Calif., Nov. 9, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of...